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Uric acid, a product of metabolism, was discovered a quarter of a millennium ago and has 
been known to be a possible cardiovascular risk factor for well over a century. A much newer 
discovery, adiponectin, was discovered only a little more than 20 years ago as a protein 
hormone secreted by adipose tissue and has attracted substantial attention for its 
association with cardiovascular disease. This thesis will examine the modifying action of 
overweight on the relationship between uric acid levels and metabolic syndrome, the 
association between uric acid levels and adverse cardiovascular events and mortality in 
subjects with or without diastolic dysfunction, and the sex-specific association between 
adiponectin levels and diastolic dysfunction. In addition, this thesis will determine whether a 
relevant interaction between uric acid and adiponectin exists with respect to diastolic 
dysfunction.  
Paper 1, a seven-year prospective study with over 6,000 participants, examines whether 
overweight modifies the association between the uric acid levels and metabolic syndrome. In 
overweight but not normal-weight subjects, the baseline uric acid levels predicted the 
development of elevated blood pressure and elevated fasting glucose levels. The baseline 
uric acid levels and changes in the uric acid levels over seven years predicted metabolic 
syndrome and most of its components. 
A 19-year prospective study of 1,460 women and 1,480 men with endpoints of all-cause 
mortality, incident myocardial infarction and incident ischaemic stroke is described in Paper 
2. Uric acid levels were a predictor of all-cause mortality in subjects with echocardiographic 
markers of diastolic dysfunction but not in subjects without these markers. Uric acid levels 
were a stronger predictor of incident ischaemic stroke in subjects with severely enlarged atria 
than in subjects with normal-sized atria.   
Paper 3 describes a cross-sectional study of 1,165 women and 896 men and the sex-specific 
relationship between adiponectin levels and diastolic dysfunction. Lower adiponectin levels 
were associated with greater odds of echocardiographic indices of diastolic dysfunction in 
women but lower odds of diastolic dysfunction in men. Additionally, lower adiponectin levels 
were associated with a higher left ventricular mass in women only. An interaction between 
uric acid and adiponectin levels was not observed for any marker of diastolic dysfunction.  
These findings support an association between uric acid levels and increased cardiovascular 
risk, with detrimental effects observed in subjects who already present a state of metabolic 
derangement and an elevated risk, such as overweight persons and subjects with diastolic 
dysfunction. Furthermore, adiponectin levels, and thus adipose tissue function, may provide 





List of presented papers  
This thesis is based on the following papers: 
 
1 Norvik JV, Storhaug HM, Ytrehus K, Jenssen TG, Zykova, SN, Eriksen BO, and 
Solbu MD. Overweight Modifies the Longitudinal Association between Uric Acid and 
some Components of the Metabolic Syndrome: The Tromsø Study. BMC Cardiovasc 
Disord. 2016;16(1):85. 
 
2 Norvik JV, Schirmer H, Ytrehus K, Storhaug HM, Jenssen TG, Eriksen BO, Mathiesen 
EB, Løchen ML, Wilsgaard T, and Solbu MD. Uric Acid Predicts Mortality and 
Ischaemic Stroke in Subjects with Diastolic Dysfunction: The Tromsø Study 1994-
2013. (Accepted for publication by ESC Heart Failure). 
 
3 Norvik JV, Schirmer H, Ytrehus K, Jenssen TG, Zykova SN, Eggen AE, Eriksen BO, 
and Solbu MD. Low Adiponectin is Associated with Diastolic Dysfunction in Women: a 






List of abbreviations 
AHA   American Heart Association 
BMI   body mass index 
CI   confidence interval 
CKD-EPI   The Chronic Kidney Disease Epidemiology Collaboration 
DD   diastolic dysfunction 
ΔUA    change in the uric acid levels 
E/A ratio  ratio of peak early left ventricular (LV) filling (E-wave) and peak late LV 
filling (A-wave) 
EDT   E-wave deceleration time 
e’   early myocardial peak velocity of the mitral annulus 
E/e’ ratio  E-wave and e’ wave ratio 
eGFR   estimated glomerular filtration rate 
Hba1c   haemoglobin a1c 
HDL   high-density lipoprotein  
HF   heart failure 
HFpEF  heart failure with preserved ejection fraction 
HFrEF   heart failure with reduced ejection fraction 
HMW   high molecular weight 
HR   hazard ratio 
IDF   International Diabetes Federation 
IVRT   isovolumetric relaxation time 
LA   left atrium 
LV   left ventricle 
MetS   metabolic syndrome 
NCEP-ATP III  National Cholesterol Education Program Adult Treatment Panel III 
NHANES  National Health and Nutrition Examination Survey 
NHLBI   National Heart, Lung, and Blood Institute 
NO    nitric oxide 
OR   odds ratio 
RCT   randomized controlled trial 
RAAS   renin-angiotensin-aldosterone-system 
ROS   reactive oxygen species 
RWT   relative wall thickness 
SD    standard deviation 
UA   uric acid 
WHO   World Health Organization 
XDH   xanthine dehydrogenase 
XO   xanthine oxidase 





1 Introduction and background 
According to the World Health Organization (WHO), 56 million people died in 20121. Of these 
individuals, 38 million died from a noncommunicable disease, diseases not passed on from 
person to person. Among the deaths due to noncommunicable disease, more than 46%, 17.5 
million deaths, resulted from cardiovascular disease, the leading cause of death worldwide. 
WHO defines premature death as death occurring before the age of 70, and the concept is a 
major consideration for evaluations of the impact of a cause of death on a population1. 
Cardiovascular disease is responsible for 37% of all premature deaths due to 
noncommunicable diseases, as shown in Figure 1. 
   
Figure 1. Left: Proportion of global deaths for individuals under the age of 70 years by cause of death. Right: 
Proportion of global noncommunicable deaths for individuals under the age of 70 years by cause of death. 
The WHO has a stated goal of reducing premature mortality due to cardiovascular diseases, 
cancer, respiratory diseases or diabetes mellitus by 25% by the year 20252. Although the 
number of deaths arising from cardiovascular disease has decreased dramatically over the 
last 40 years in Norway, particularly in the group < 70 years of age, it is still the leading 
cause of death in this country3. One study examining the decline in acute coronary heart 
disease in Tromsø between 1994 and 2008 attributed 66% of the decrease to reductions in 
population risk factors, such as cessation of smoking and reduction of blood pressure and 
cholesterol levels4. An increase in the populations who are overweight or have diabetes 
mellitus type 2 has hampered the decrease in coronary heart disease4. There is, however, 
desire and room for the improvement of risk estimation, and the American Heart Association 
(AHA) recommends conducting research to fill gaps in knowledge about cardiovascular risk 
assessment and outcomes5. 
Metabolic syndrome (MetS), which is strongly associated with overweight and obesity, is a 
cluster of risk factors for cardiovascular disease6. Uric acid (UA) has long been linked with 
MetS7 and cardiovascular disease8, but the possible modulatory effect of overweight on the 





























Diastolic dysfunction (DD) is a pathological state characterized by abnormal cardiac 
relaxation, stiffness or filling and is closely associated with heart failure (HF) with preserved 
ejection fraction (HFpEF)9. Overweight and obesity are prevalent in subjects with HFpEF10. 
DD itself11 and HFpEF12 are associated with increased mortality. A medical treatment with a 
proven benefit for HFpEF is not available13. The effect of UA levels on mortality and 
cardiovascular events in subjects with DD has not been thoroughly studied. 
Adiponectin is a hormone secreted mainly by adipocytes14, and low serum adiponectin levels 
are generally associated with cardiovascular disease15 and obesity16. Sex-specific 
differences in adiponectin levels have been observed in that women in general have higher 
plasma concentrations17. HFpEF exhibits a female preponderance, and the basis for this 
preponderance is a stated direction for future research10. The association between DD and 
adiponectin levels, as well as the sex-specific differences related to this association, warrant 
investigation. UA may affect adipocytes by inducing the downregulation of adiponectin18, and 
the association between the UA and adiponectin levels in DD is not known. 
Cardiovascular disease is the main cause of death worldwide, and the global goal is to 
reduce cardiovascular mortality. Investigations of modifiable risk factors for and biomarkers 
of cardiovascular disease will contribute to our ability to achieve this goal. In the present 
thesis, we specifically address, for the first time, the interrelationships between UA levels, 
MetS, adiponectin levels, indices of DD and the future development of cardiovascular 
disease and mortality in a large, middle-aged to elderly cohort from the general population, 
2 Metabolic syndrome 
2.1.1 Definitions 
Physicians have been aware for decades of an established set of interrelated risk factors for 
cardiovascular disease and diabetes that tend to cluster. In 1923, the Swedish medical 
doctor Eskil Kylin observed a syndrome that was associated with an increased risk of 
cardiovascular disease and was characterized by hypertension, hyperglycaemia, and 
hyperuricaemia, which is one of the first descriptions of the clustering of these risk factors19. 
Modern studies of this phenomenon began after the 1988 Banting Lecture to the American 
Diabetes Association, during which Gerald M. Reaven introduced insulin resistance as the 
major factor in the syndrome, coining it “syndrome X”20. Consequently, this syndrome was 
renamed “insulin-resistance syndrome” in 199221. The label “metabolic syndrome”, which is 
currently the most common name for this syndrome, was first proposed in 198122 and was 
the term used by a consultant group for the WHO in 1998 in an initial attempt to formalize 
diagnostic criteria for the syndrome7. In this definition, insulin resistance is a prerequisite for 
the diagnosis of MetS, in addition to two or more additional risk factors, including 
hypertension, elevated triglyceride levels, central or general obesity and microalbuminuria. In 
2001, the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) 
published their definition of MetS23. The NCEP-ATP III criteria did not have any single feature 
as a prerequisite for the diagnosis. Rather, the presence of three or more of the following 
factors was required for diagnosis: elevated waist circumference, elevated triglyceride levels, 
reduced high-density lipoprotein (HDL) cholesterol levels, elevated blood pressure and 
elevated fasting glucose levels. In 2005, AHA and the National Heart, Lung, and Blood 
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Institute (NHLBI), as well as the International Diabetes Federation (IDF) attempted to reach a 
common definition for MetS. Although the AHA/NHBLI criteria were almost identical to the 
NCEP-ATP III criteria24, the IDF definition included central obesity as a precondition in 
addition to any two or more of the other four criteria from the NCEP-ATP III classification as a 
requirement for the diagnosis of MetS25. Nevertheless, in 2009, the groups reached a 
consensus, and IDF, NHLBI, AHA, the World Heart Federation, the International 
Atherosclerosis Society, and the International Association for the Study of Obesity released a 
joint scientific statement6. This definition of MetS did not have any one required feature, and 
three or more of five factors were established as requirements for diagnosis. These criteria 
were the same as the revised NCEP-ATP III criteria published by AHA/NHBLI, with the 
exception of population-specific waistline cut-off points, and are the basis for the definition of 
MetS used throughout this dissertation. Some researchers disagreed regarding the cut-off 
points for waist circumference. For Europids, the IDF recommended a threshold of ≥ 80 cm 
for women and ≥ 94 cm for men; the AHA/NHLBI recommended a threshold of ≥ 88 cm for 
women and ≥ 102 cm for men. The latter cut-offs are used to diagnose MetS in this thesis. 
However, due to lack of fasting blood samples, the AHA/NHBLI cut-off points have been 
modified in the present work. The AHA/NHBLI definition of MetS and the modified 
AHA/NHBLI definition employed here are summarized in Table 1. 
Table 1. Three or more of the following five criteria constitute a diagnosis of metabolic syndrome. 
Measure AHA/NHBLI MetS definition paper 1 
Elevated waist 
circumference 
≥ 88 cm in women, ≥ 102 cm 
in men 
≥ 88 cm in women, ≥ 102 cm in 
men 
Elevated 
triglyceride levels  
≥ 1.7 mmol/L or on fibrates or 
nicotinic acid 
≥ 1.7 mmol/L if the time since the 
last meal is ≥ 4 hours or ≥ 2.28 
mmol/L if the time since the last 
meal is < 4 hours or the subject 
uses fibrates or nicotinic acid 
Reduced HDL 
cholesterol levels 
< 1.3 mmol/L in women, < 1.0 
mmol/L in men or use of 
fibrates or nicotinic acid 
< 1.3 mmol/L in women, < 1.0 




systolic ≥ 130 mm Hg or 
diastolic ≥ 85 mm Hg or use of 
antihypertensive treatment 
systolic ≥ 130 mm Hg or diastolic  




≥ 5.6 mmol/L or use of a 
glucose-lowering treatment 
≥ 5.6 mmol/L if the time since the 
last meal is ≥ 4 hours or ≥ 7.8 
mmol/L if the time since the last 
meal is < 4 hours or the subject 





One investigator estimated the prevalence of MetS to range from < 10% to 84%, depending 
on the region, demographics of the population studied and definition of MetS used19. For 
example, the waist circumference cut point employed by the IDF would encompass more 
people than the definition from AHA/NHBLI. Based on estimates from the IDF, the worldwide 
prevalence was approximately 20-25%26. In the National Health and Nutrition Examination 
Survey (NHANES) 2003-2006, approximately 34% of US adults aged ≥ 34 years had MetS27. 
In one study, the prevalence of MetS in Northern Norway in 2003-2004 was reported to be 
approximately 18% when the AHA/NHBLI cut-off was used for waist circumference and 
approximately 26% when the IDF cut point was used28. The prevalence of MetS significantly 
increased between NHANES 1988-1994 and NHANES 1999-2006, and one of the main 
reasons for this change was the surge in abdominal obesity29. The syndrome is common, 
and its prevalence is increasing worldwide6. 
2.1.3 Metabolic syndrome as a risk factor 
The reason why diagnostic criteria were created for MetS was for the early identification of 
persons at risk of developing diabetes and cardiovascular disease and, consequently, for 
promoting lifestyle changes or initiating medical treatment. Although a few studies failed to 
observe an association between MetS and cardiovascular disease, most studies identified a 
strong relationship between MetS and cardiovascular disease30, which is not surprising 
because all the components of MetS have long been known as major cardiovascular risk 
factors30. This relationship leads to the question of whether MetS offers diagnostic value 
beyond the individual component risk factors that comprise the syndrome. One 11-year 
prospective study with more than 12,000 participants showed that subjects with MetS had an 
increased risk of cardiovascular disease, although the diagnosis of MetS did not suggest a 
greater risk than the risk explained by the presence of its individual components31. Moreover, 
MetS has been suggested to be a weaker tool for predicting the risk of cardiovascular 
disease than the traditional Framingham criteria30. However, many view MetS as a real and 
progressive pathophysiological state with risk factors that are causally interrelated32. One 
meta-analysis examining 87 studies with a total of nearly one million subjects found that 
persons with MetS had double the risk of cardiovascular disease and cardiovascular 
mortality, with a median follow-up time of 12.3 years8. Furthermore, subjects with MetS have 
a five-fold increased risk of developing type 2 diabetes mellitus6. The CardioMetabolic Health 
Alliance recognizes that additional factors that are not incorporated in the MetS are related to 
the syndrome and are associated with adverse outcomes32. Therefore, the identification of 
features associated with MetS, such as an easily and inexpensively modifiable risk factor, is 
a worthwhile endeavour.  
2.2 Diastolic dysfunction 
2.2.1 Definitions 
Diastole is the interval between aortic valve closure and mitral valve closure38. Impairment of 
left ventricular (LV) relaxation, LV compliance and filling pressures may result in impaired LV 
filling or suction capacity and cause DD9,33 . DD is closely associated with HFpEF, a clinical 
syndrome with symptoms (such as dyspnoea and fatigue) that may be accompanied by signs 
(such as elevated jugular venous pressure, pulmonary crepitation and peripheral oedema) of 
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heart failure (HF), and a normal or slightly reduced LV ejection fraction9. DD can worsen over 
time and poses a risk for HFpEF34. In the 2016 European Society of Cardiology guidelines for 
the diagnosis and treatment of acute and chronic HF, the diagnosis of HFpEF requires 
symptoms with or without signs of HF and LV ejection fraction ≥ 50% (plus elevated 
natriuretic peptide levels, if available), plus at least one additional criterion: a relevant 
structural heart disease (LV hypertrophy or left atrial (LA) enlargement) or other indices of 
DD9. The indices of DD used in this dissertation are based on these guidelines and 
previously published data and are listed in Table 235–37. 
Table 2. Echocardiographic indices of diastolic dysfunction. 
Index Normal values Diastolic 
dysfunction 
Paper 2 
Diastolic dysfunction Paper 
3 
E/A ratio Paper 2: 0.75-1.5 
Paper 3: 0.75-2.0 
< 0.75 or > 1.5 < 0.75 or > 2.0 
EDT 140-220 ms  < 140 ms or        
> 220 ms 
< 140 ms or > 220 ms 
IVRT Paper 2: > 60 ms 
Paper 3: 60-110 ms 
 ≤ 60 ms < 60 ms or > 110 ms 
LA size < 2.2 cm/m2 Moderately 
enlarged 2.2-
2.79 cm/m2 or 
severely 
enlarged ≥ 2.8 
cm/m2 
Moderately enlarged 2.2-2.79 
cm/m2 or severely enlarged ≥ 
2.8 cm/m2 
E’-wave ≥ 9 cm/s Not applicable < 9 cm/s 
E/e’ ratio < 8 Not applicable ≥ 8 
LV remodelling LV mass ≤ 95 g/m² 
in women, ≤ 115 
g/m² in men, and 
RWT ≤ 0.42 
Not applicable Concentric remodelling: LV 
mass ≤ 95 g/m² in women or ≤ 
115 g/m² in men, and RWT > 
0.42; concentric hypertrophy: 
LV mass > 95 g/m² in women 
or > 115 g/m² in men, and 
RWT > 0.42; eccentric 
hypertrophy: LV mass > 95 
g/m² in women or > 115 g/m² 
in men, and RWT < 0.42 
Abbreviations: E/A ratio, E-wave/A-wave ratio; EDT, E-wave deceleration time; IVRT, isovolumetric relaxation 
time; LA, left atrium; E/e’ ratio, E-wave/e’-wave ratio; LV, left ventricle; RWT, relative wall thickness. 
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The indices of DD can be acquired through regular transthoracic echocardiography in the 
clinic. Three of the indices, E/A ratio, EDT and IVRT, are acquired by placing the Doppler 
probe in the mitral ostium and registering the velocity of the LV inflow from the LA during 
diastole33,38. A schematic of a transmitral flow profile is shown in Figure 2.  
 
Figure 2. Schematic of transmitral flow. Abbreviations: A, A-wave; E, E-wave; EDT; E-wave deceleration time; 
IVRT, isovolumetric relaxation time. 
Diastolic flow across the mitral valve has two peaks: the E-wave, showing the early, passive 
filling of the LV, and the A-wave, showing the late, active filling as a result of atrial 
contraction33,38. The E-wave reflects the pressure gradient between the LA and the LV during 
early diastole, is affected by the rate of LV relaxation and the LA pressure33,38. The A-wave 
reflects the pressure gradient between the LA and the LV during late diastole, and is affected 
by LA contractile function and LV compliance33,38. A reduced ratio of the velocity of the E-
wave and the A-wave, the E/A ratio, is associated with impaired LV relaxation, and an 
increased E/A ratio is associated with restrictive filling33,38. The E-wave (EDT) deceleration 
time is the duration of the interval between peak early diastolic filling, the apex of the E-wave, 
and the end of the E-wave33,38. The isovolumetric relaxation time (IVRT) is the duration of the 
interval between the closing of the aortic valve and the opening of the mitral valve33,38. A 
decreased EDT or IVRT indicates restrictive LV physiology, and an increased EDT or IVRT 
indicates impaired LV relaxation33,38. The LA size reflects the effects of increased LV filling 
pressures over time33,38. The three Doppler measurements described above are acquired by 
reflection of signals from moving blood cells, in contrast to tissue Doppler imaging, which is 
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based on reflections from moving myocardium33. The e’-wave a recording of the moving 
myocardium approximately 1 cm apical of the mitral valve during early diastolic filling33. This 
thesis uses the average velocity of the e’-waves captured near the septal and lateral leaflets 
of the mitral valve. Reduced e’-wave is associated with impaired LV relaxation38. An elevated 
ratio of the E-wave and the e’-wave is associated with increased LV filling pressures38. 
Pathological LV remodeling is associated with associated with LV stiffness and DD38. 
2.2.2 Epidemiology and prognosis 
In developed countries, the prevalence of HF is approximately 1-2% of the adult population 
and ≥ 10% of people > 70 years of age9. Approximately half of patients with HF have 
HFpEF39. Some researchers have reported an approximately 1% annual increase in the 
prevalence of HFpEF in the population with HF40. In contrast to patients with HF with reduced 
ejection fraction (HFrEF), patients with HFpEF tend to be older, more frequently are women 
and more often present a history of hypertension9. The reasons for the female 
preponderance of HFpEF are unknown10. Atrial fibrillation, obesity, diabetes mellitus and 
hyperlipidaemia are other disorders that are highly prevalent in the population with HFpEF39. 
The EURObservational Research Programme: the Heart Failure Pilot Survey (ESC_HF Pilot) 
conducted a prospective 1-year survey among 136 cardiology centres in 12 countries with 
over 5,000 enrolled patients with HF and confirmed that HF is a major health problem12. The 
all-cause mortality rate after one year was 13.4% for patients with acute HFpEF and 5.9% for 
patients with chronic, stable HFpEF, and the overall hospitalization rates for the population 
with HF were 43.9% for patients with acute HF and 31.9% for patients with chronic HF. The 
study did identify somewhat lower mortality rates for patients with HFpEF than for patients 
with HFrEF. Other researchers have previously suggested that the prognosis is 
comparable41. DD not accompanied by HF is associated with increased all-cause mortality 
and is often asymptomatic11. In contrast to HFrEF, a medical treatment with a proven benefit 
for HFpEF or DD is not available42, and therapy focuses on alleviating symptoms and treating 
comorbidities, such as hypertension, volume overload and atrial fibrillation9. Overall, a 
disease-specific understanding of HFpEF is lacking, and thus more knowledge about 
modifiable risk factors associated with HFpEF is needed. Indeed, investigations designed to 
elucidate the contributions of metabolic disturbances are warranted, given the high 
prevalence of obesity, dyslipidaemia, diabetes mellitus, and MetS in subjects with HFpEF. In 
addition, research is needed to shed light on its female preponderance10. 
2.3 Uric acid 
2.3.1 Production and metabolism 
UA is the end stage of purine metabolism in humans and is the breakdown product of 
molecules such as nucleic acids (DNA and RNA) and adenosine triphosphate (ATP). 
Humans and most primates are almost the only mammals with high serum UA levels 
because the gene encoding the uricase enzyme became a pseudo-gene during evolution43. 
Some researchers have hypothesized that the gene became non-functional in early hominids 
approximately 15 million years ago as a consequence of the shift in diet due to climate 
change44. This change may have provided some survival advantage during times of food 
shortage because an elevated UA level may augment the storage of energy from fructose in 
fruits as fat44. Uricase metabolizes UA into allantoin, which is freely excreted in the urine; 
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therefore, most mammals have low UA levels - approximately 60 µmol/L. In contrast, UA is 
not as easily excreted, and normal humans have serum UA levels approaching – and often 
exceeding – the theoretical limit of UA solubility in serum (approximately 400 µmol/L)45. UA 
metabolism is displayed schematically in Figure 3. Xanthine oxidoreductase (XOR) degrades 
hypoxanthine to xanthine and xanthine into UA, and exists in two forms, xanthine 
dehydrogenase (XDH) and xanthine oxidase (XO)46. XOR mostly occurs in its XDH form, but 
proteolytic cleavage or oxidation transforms the enzyme to xanthine oxidase (XO)47. In its XO 
form, reactive oxygen species (ROS) are a by-product of the degradation of hypoxanthine to 
xanthine and xanthine to UA46. 
 
Figure 3. Diagram of purine metabolism. Humans lack uricase, and hence uric acid is the end product. 
2.3.2 Hyperuricaemia   
Approximately one-third of the total body UA is obtained exogenously, originating from 
dietary purines (particularly from purine-rich foods such as red meats, organ meats and 
shellfish), and the remainder is endogenously produced46. Ethanol will greatly increase 
production because of ATP turnover during metabolism, as will fructose intake46. 
Approximately one-third of UA excretion occurs via the gastrointestinal tract, and the two-
thirds occurs by urinary excretion46. Consequently, high levels of serum UA, hyperuricaemia, 
is caused by overproduction of UA or reduced excretion, the latter being the most frequent 
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occurrence48. Traditional risk factors for hyperuricaemia are alcohol consumption, diuretic 
and low-dose aspirin use, a Western diet, a sedentary lifestyle, obesity, male gender and 
age49–51. The classification of hyperuricaemia varies between studies and countries; in some 
studies, hyperuricaemia has “arbitrarily” been defined as approximately > 389 µmol/L in 
women and > 416 µmol/L in men46. The NHANES studies has defined hyperuricaemia as > 
339 µmol/L in women and > 416 µmol/L in men51. Table 3 lists the reference values for the 
serum UA levels provided by the laboratory at the University Hospital of North Norway. The 
reason for the different UA levels for pre- and post-menopausal women is a possible 
influence of oestrogen on UA reabsorption in the renal proximal tubule52. 
Table 3. Reference values for uric acid at the University Hospital of North Norway. 
Women 18-49 years 155-350 µmol/L 
Women ≥ 50 years 155-400 µmol/L  
Men ≥ 18 years 230-480 µmol/L 
 
Sustained hyperuricaemia above the limit of UA solubility in serum (and thus the limit of 
monosodium urate crystal formation) is a prerequisite for gout53, which is the most common 
of the three major urate crystal deposition-related disorders: gout, urate nephropathy and 
nephrolithiasis. These disorders are currently the only diseases caused by hyperuricaemia 
for which there is an indication for medical treatment in Europe and the USA; 
recommendations for the treatment of asymptomatic hyperuricaemia are not available54. The 
NHANES 2007-2008 examined US adults and found that the prevalence of hyperuricaemia 
was 21.6% in women and 21.2% in men51. Similar prevalences have been reported in 
studies conducted in Thailand55, Japan56 and China57. However, a minority of people with 
hyperuricaemia suffer from gout. In one study, only 22% of persons with UA levels > 535 
µmol/L developed gout during a 5-year period58. The prevalence of hyperuricaemia is 
increasing, as evidenced by the increase in the incidence of gout since the 1960s53, which 
increases as UA levels increase58. This increase is believed to be related to the increases in 
populations with adiposity and hypertension, as well as the increased use of diuretics and 
low-dose aspirin51. 
2.3.3 Uric acid as a risk factor 
Although treatments for hyperuricaemia are not recommended unless it causes a crystal 
deposition-related disorder, UA has been implicated in several other conditions not related to 
crystal disposition. The consequences of hyperuricaemia were first recorded in 2640 BC 
when the Egyptians identified gout59. UA was discovered in 1776 by the Swedish chemist 
Carl Wilhelm Scheele60, and in 1859, Sir Alfred Baring Garrod stated that the deposition of 
UA is the cause of gouty inflammation59. As early as the 1870s, the British physician 
Frederick A. Mahomed linked hyperuricaemia to hypertension60, and it has since been 
associated with several other disorders that are not caused by crystal disposition, such as 
obesity, chronic kidney disease, preeclampsia, diabetes, MetS and cardiovascular disease61. 
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UA has the strongest association with hypertension with regards to cardiovascular risk; some 
researchers have claimed that hyperuricaemia is currently the most reproducible 
independent risk factor for hypertension62. A meta-analysis of 18 prospective studies with 
more than 55,000 participants found that hyperuricaemia is associated with an increased risk 
of hypertension with a pooled relative risk of 1.13 per 59 µmol/L increase in the UA levels63. 
Numerous studies have defined UA as a risk factor for cardiovascular disease. NHANES 
1971-1992 identified increased UA levels as a risk factor for ischaemic heart disease 
mortality and total cardiovascular mortality in both men and women and a risk factor for all-
cause mortality in women64. A prospective study of more than 400,000 subjects with a follow-
up time of approximately 12 years identified UA as a risk factor for myocardial infarction, 
stroke and congestive HF65. A publication from the Tromsø Study examined UA levels in a 
15-year prospective study and found that UA levels were associated with all-cause mortality 
and ischaemic stroke66. A Finnish study of more than 1,400 men with a follow-up time of 
approximately 12 years stated that UA levels were a strong predictor of cardiovascular death 
and all-cause mortality67. However, several studies have disputed the hypothesis that UA 
levels are a cardiovascular risk factor, most notably the Framingham Heart Study with 6,763 
participants, in which UA levels were not an independent risk factor for coronary heart 
disease, cardiovascular death or all-cause mortality after a complete adjustment of the 
models68. The authors argued that UA was associated with other factors associated with 
cardiovascular disease and death (i.e., confounders), particularly the use of diuretics, and not 
the outcomes per se. This discrepancy highlights the major controversy regarding this topic: 
is UA a causal risk factor for cardiovascular disease or is it merely linked to other factors 
associated with cardiovascular disease?  
With regards to MetS, the 1998 WHO definition noted that although hyperuricaemia had 
been suggested to be a component of MetS, it was not required for diagnosis7. However, a 
position statement on MetS by the American College of Endocrinology in 2003 did identify 
UA as a component of the syndrome69, but no major guideline currently establishes UA as a 
major factor of MetS. Nonetheless, in 2015, The CardioMetabolic Think Tank published a 
new care model for patients with MetS, in which they proposed MetS subtypes and 
recognized hyperuricaemia as a possible pathophysiological foundation for one subtype, 
along with other risk factors that are not featured in the guideline criteria for MetS32. 
According to NHANES 1988-1994, the prevalence of MetS was substantially increased as 
UA levels increased and the prevalence exceeding 70% in subjects with UA levels > 590 
µmol/L70. A meta-analysis based on 11 prospective studies and nearly 60,000 subjects 
discovered that higher UA levels led to an elevated risk of MetS based on a linear dose-
response relationship, with a relative risk of 1.30 per 59 µmol/L increase in the UA level71. 
However, researchers have not determined whether UA is a predictor of the development of 
MetS in all subjects or in subgroups of the population. 
2.4 Adiponectin 
2.4.1 History, production and action 
Adiponectin, a protein that is specifically produced by adipocytes, was discovered in 1995 
and was coined Acrp30 (adipocyte complement-related protein of 30 kDa)72. It belongs to a 
group of protein hormones known as adipokines that are produced by adipose tissue14. 
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Adipokines regulate energy metabolism, insulin sensitivity, inflammation, atherosclerosis and 
cell proliferation14. Biologically important members include, among others, tumour necrosis 
factor-α, interleukin-6, interleukin-10, omentin, leptin and adiponectin73. Adiponectin is 
present at high levels in healthy humans and comprises approximately 0.01% of the total 
plasma protein74. The normal range is approximately 5-10 µg/mL, and women generally have 
higher levels than men17, and adiponectin shows a negative correlation with testosterone75. 
Three subtypes of adiponectin receptors (AdipoR1, AdipoR2, and T-cadherin) have been 
identified, present in skeletal muscle, liver, vasculature and several other places76 
Adiponectin is not routinely measured in the clinic. Adiponectin has been shown to be an 
insulin-sensitizing protein that protects the vasculature and has anti-inflammatory 
properties77. Adiponectin is separated into three complexes: a low molecular weight form, a 
middle molecular weight form, and a high molecular weight (HMW) form. The dissimilarity in 
adiponectin levels between men and women may be solely due to a higher level of the HWM 
form in women than in men78. 
2.4.2 Adiponectin as a risk factor 
Low levels of adiponectin are associated with the development of insulin resistance79, 
hypertension80, metabolic syndrome81 and a higher risk of myocardial infarction15; 
adiponectin is also negatively correlated with body mass index (BMI) and body fat16. These 
observations comply with the traditional view that high adiponectin levels are favourable in 
terms of cardiac health. However, several studies have challenged this view. In one study, a 
high adiponectin level was a predictor of mortality in patients with HFrEF and a marker of HF 
severity82. This study is part of a growing body of evidence showing that although 
adiponectin is generally viewed as protective, higher levels are observed in patients with 
chronic HF and increase with disease severity, particularly in the presence of cardiac 
cachexia83. A meta-analysis of 15 prospective studies and 1 nested case control study with 
more than 14,000 patients with established cardiovascular disease found that increased 
baseline adiponectin levels were associated with an elevated risk of all-cause mortality and 
cardiovascular mortality84. Some investigators have suggested that this increased risk is due 
to an upregulation of the adiponectin levels to compensate for increased oxidative stress and 
inflammation85. High adiponectin levels are also associated with chronic kidney disease and 
a reduced glomerular filtration rate (GFR), possibly due to low clearance rates86 or as a 
compensatory mechanism for adiponectin resistance or chronic inflammation87. However, not 
all investigations have identified an association between adiponectin levels and 
cardiovascular disease. A meta-analysis of 16 prospective studies including approximately 
24,000 patients did not identify a relationship between adiponectin levels and incident 
coronary heart disease or stroke88. Some studies have examined the relationship between 
adiponectin levels and DD. In one study of 77 healthy subjects, the adiponectin levels were 
negatively correlated with two of the markers of DD applied in this thesis, e’ and LV mass, in 
linear regression analyses89. The Framingham Offspring Study examined the relationship 
between the adiponectin levels and cardiac remodelling and discovered a lower LV mass in 
patients in the higher adiponectin quartiles90. However, the authors did not observe an 
association between the adiponectin levels and LA size when the models were fully adjusted. 
UA has been postulated to affect adipocytes by downregulating the adiponectin levels18, and 
a biologically relevant interaction between uric acid and adiponectin may exist. However, any 
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association between adiponectin and UA in disease may be confounded by a reduced GFR, 
in which both UA and adiponectin levels are known to be elevated, and the analyses must 
therefore control for kidney function. 
3 Aims of the thesis 
We aimed to examine the relationship between the plasma levels of UA and adiponectin with 
the often-coexisting pathological states of MetS and DD, which are connected by risk factors 
such as overweight, hypertension, diabetes mellitus and chronic kidney disease. The aims of 
the thesis were: 
• To examine the relationship between UA levels and MetS, specifically the 
modulatory effect of overweight on the relationship. 
• To study the effect of UA levels on the association between indices of DD and 
adverse outcomes. 
• To investigate the association between adiponectin levels and DD and 
determine whether this association is sex specific.  
• To ascertain whether there is an interaction between UA and adiponectin for 
the association with DD.  
4 Study population and methods 
4.1 The Tromsø Study 
Tromsø is the largest city of Northern Norway and its municipality had 73,480 inhabitants by 
January 1 2016, with 65,189 of the people within the city limits91. The Tromsø Study is a 
series of surveys conducted on the inhabitants of the municipality of Tromsø since 197492, 
and is a population-based prospective study on a mostly healthy, middle-aged to elderly, 
Caucasian population93,94. This study was initiated as a measure to prevent the high mortality 
of cardiovascular diseases in men in Northers Norway, and seven surveys of the study series 
have been completed 6-7 years apart92,94. From the second wave in 1979-98 and onwards, 
women were included in the surveys94. The surveys all include questionnaire data, sampling 
of biological specimens and clinical measurements93. The study was initiated, and is run and 
owned, by the University of Tromsø93. It was originally funded by The University of Tromsø – 
The Arctic University of Norway, and still is, but receives today considerable contributions 
from the National Screening Services, the Research Council of Norway, Northern Norway 
Regional Health Authority, Norwegian Council on Cardiovascular Diseases and Norwegian 
Foundation for Health and Rehabilitation92. This thesis uses data from the fourth, fifth and 
sixth waves of the Tromsø Study, which were conducted in 1994-95, 2001-02 and 2007-08, 
respectively. 
4.1.1 The Tromsø 4 study population 
The fourth wave of the Tromsø Study series was the largest, was conducted in 1994-95, and 
all inhabitants of Tromsø ≥ 25 years were invited to participate. A total of 27,158 persons 
participated in this study, amounting to a 77% eligibility rate after exclusion of the individuals 
who died or moved from the municipality between the time of the invitation and the time of 
the survey. Among these individuals, all women and men aged 55–74 years, as well as 
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smaller (5–8%) random samples of the other age groups < 85 years, were invited to an 
extended examination. This special study included echocardiography and UA measurements 
among other measurements, and 7,665 subjects participated (75% of the eligible subjects). 
4.1.2 The Tromsø 5 study population 
For the Tromsø Study of 2001-02, all subjects from the special study of Tromsø 4 plus a 
smaller sample from the 30, 40, 45, 60 or 75-year-old age groups were invited, and 8,130 
were enrolled (76% of eligible subjects). At 89%, the enrolment rate was high among 
persons who had previously participated in Tromsø 4 seven years prior to this study, and this 
group was invited to an extended, special examination. A total of 5,939 subjects agreed to 
participate in the special survey (85% of eligible subjects). 
4.1.3 The Tromsø 6 study population 
The sixth survey of the Tromsø Study was conducted in 2007-08, and four distinct groups 
were invited: subjects who participated in the special study of Tromsø 4, a 10% random 
sample of persons aged 30-39, a 40% random sample of subjects aged 43-59 years, and all 
individuals aged 40-42 or 60-87 years. A total of 12,984 subjects were enrolled (66% of the 
invited population). In addition, all subjects from the special study of Tromsø 4 who were 
aged 50-62 or 75-84 years, plus a 20% random sample of subjects aged 63-74 years old, 
were invited to participate in a special examination. Among the 11,484 eligible subjects, 
7,307 persons participated (64% participation rate). The special study included adiponectin 
measurements and echocardiography. 
4.1.4 The study populations assessed in the papers in this thesis 
Paper 1 examines the subjects that attended the special studies from both Tromsø 4 and 
Tromsø 5. We excluded subjects with missing serum UA analyses (n = 405), prevalent 
diabetes at baseline (n = 282; defined as Hba1c ≥ 6.5%, non-fasting glucose ≥ 10.0 mmol/L, 
under anti-diabetic treatment or self-reported diabetes), and underweight subjects (n = 82, 
BMI < 18.5 kg/m2). The final study cohort consisted of 6,083 subjects at baseline. 
The population evaluated in Paper 2 consisted of the individuals who participated in the 
special study from Tromsø 4. Of these individuals, 7,445 persons had serum UA 
measurements, and 3,272 were randomly selected for echocardiography. A total of 3,068 
subjects underwent both UA measurements and echocardiography. We excluded the 
individuals with diabetes at baseline (n = 128). Thus, the final cohort consisted of 2,940 
subjects. 
Paper 3 examined the people who participated in the special survey from Tromsø 6. Among 
these individuals, 2,243 people were randomly selected and underwent echocardiography. 
We again excluded the subjects with prevalent diabetes at baseline (n = 182), resulting in 
2,061 subjects who were enrolled in the final cohort. 
4.2 Measurements and clinical variables 
All subjects completed a self-administered questionnaire that provided information on their 
current use of medication, diabetes, smoking habits, alcohol consumption, and physical 
activity. Experienced nurses performed the anthropometric measurements. Blood pressure 
was recorded in triplicate, and we used the mean of the second and third measurements. We 
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classified physical activity as active (≥ 1 hour of physical activity with prominent perspiration 
or breathlessness per week) or inactive (all others), and smoking habits were classified as 
current smokers and non-smokers. 
4.2.1 Blood samples 
Serum UA levels were measured by spectrophotometry with COBAS instruments (Roche 
diagnostics, Switzerland) using an enzymatic colorimetric test known as the uricase/phenol-
amino-phenazone (PAP) method. Serum specimens from participants in Tromsø 6 were 
stored at -70°C, thawed and analysed for the total adiponectin levels in 2012. Adiponectin 
levels were analysed using an ELISA (DY1065 kit from R&D Systems, Inc., Minneapolis, 
MN). 
Originally, the plasma creatinine levels in participants in Tromsø 4 and Tromsø 5 were 
analysed using a modified Jaffe reaction, an indirect colorimetric method of measuring 
creatinine levels95. However, because of a possible drift in the results between baseline and 
follow-up, 111 plasma samples from participants in Tromsø 4 and 142 samples from 
participants in the Tromsø 5 studies were thawed and reanalysed in 2006 using an 
enzymatic method (Modular P/Roche Diagnostics). These results were then fitted to a linear 
regression model, and the creatinine levels for all participants in those two surveys were 
recalibrated. In Tromsø 6, the plasma creatinine levels were measured using an enzymatic 
method that has been standardized using isotope dilution mass spectrometry (CREA Plus, 
Roche Diagnostics, GmbH, Mannheim, Germany). We calculated the estimated glomerular 
filtration rate (eGFR) for the subjects included in Paper 1 and Paper 2 according to The 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula96. Because cystatin 
C measurements were available for the participants in Tromsø 6, we calculated the eGFR for 
the participants in Paper 3 according to the CKD-EPI creatinine-cystatin C equation, which is 
superior to the CKD-EPI formula97. 
Since blood samples were obtained from non-fasting subjects in all surveys, the MetS 
definition applied in Paper 1 was modified to compensate for the non-fasting glucose and 
triglyceride levels, as described above (Table 1) and discussed below. 
4.2.2 Echocardiography 
The echocardiography procedures in Tromsø 4 were performed with a Vingmed CFM 750 
(Vingmed Sound A/S, Horten, Norway) combined with a 3.25-MHz mechanical and 2.5-MHz 
Doppler probe.  
The echocardiography procedures in Tromsø 6 were performed with an Acuson Sequoia 
C512 Ultrasound System (Siemens Medical Solutions. Mountain View, California, USA) with 
a combined 3.5-MHz second harmonic ultrasound and 2.5-MHz Doppler probe.  
We calculated LV mass using the cube formula at end-diastole (LV mass = 0.8 x [1.04 x 
{interventricular septum thickness + LV internal diameter + posterior wall thickness}3 – {LV 
internal diameter}3] + 0.6 g)98. We calculated the relative wall thickness (RWT) as (relative 
wall thickness = [2 x posterior wall thickness]/LV internal diameter at end-diastole)98.  
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We indexed the LA size and LV mass by the body surface area calculated using the Du Bois 
formula (body surface area = [weight {kg} 0.425 × height {cm} 0.725] x 0.007184) in both Paper 2 
and Paper 335. 
Due to technological advancements and new guidelines, there were discrepancies between 
the indices of DD studied in Paper 2 and Paper 3. Tissue Doppler was not available in 
Tromsø 4, and therefore Paper 2 does not include any markers of DD based on Tissue 
Doppler measurements. The European Society of Cardiology published new guidelines for 
echocardiographic LV diastolic assessments in the time between the submission of Papers 2 
and 3, which affected the indices of DD applied in Paper 3. Specifically, the upper normal 
limit for the E/A ratio was increased from 1.5 in Paper 2 to 2.0 in Paper 3, and an upper limit 
for IVRT was added, according to the new guidelines9. In addition, the subjects with an IVRT 
of exactly 60 ms were in Paper 3 within the normal range. In contrast to Paper 3, Paper 2 did 
not use LV mass as a marker of DD. The indices of DD for both papers are listed in Table 2. 
4.3 Assessment of endpoints 
Paper 2 utilizes the endpoints all-cause mortality, first-ever fatal or non-fatal myocardial 
infarction and first-ever fatal or non-fatal ischaemic stroke for the 2,940 subjects in the study. 
The endpoints were identified by linkage to the diagnosis registry at the University Hospital of 
North Norway and the National Causes of Death Registry. An independent endpoint 
committee evaluated hospital and out-of-hospital journals, autopsy records and death 
certificates to adjudicate each event. The committee identified myocardial infarctions and 
ischaemic strokes by examining the diagnosis registries at the University Hospital of North 
Norway (outpatient diagnoses included) and the National Causes of Death Registry through 
a search for the International Classification of Diseases, Ninth Revision (ICD-9) codes 410-
414, 427, 428, 430-438, and 798-799 and ICD-10 codes I20-I25, I46-I48, I50, I60-I69, R96, 
R98, and R99. The events were classified using the Modified World Health Organization 
Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) and MONICA 
Risk, Genetics, Archiving and Monograph (MORGAM) manuals. Information on emigration 
from the municipality, from Norway, and date of death was obtained from the National 
Registry of Norway. The endpoint registry was completed through December 31, 2013 (19 
years) for all-cause mortality and through December 31, 2012 (18 years) for myocardial 
infarction and ischaemic stroke. For all-cause mortality data, we censored for emigration 
from Norway. For myocardial infarction and ischaemic stroke, we censored for migration out 
of the municipality or Norway, and death from other causes than incident myocardial 
infarction and incident ischaemic stroke, respectively. 
4.4 Statistical analysis 
Baseline data are presented as the means ± standard deviations (SD) for continuous 
variables and as numbers and percentages for categorical variables. Student’s t-test and the 
chi square test were used to examine the differences between the continuous and 
categorical variables in two groups. In Paper 1, logistic regression analyses were used to 
examine the relationship between the UA levels and the components of MetS and the 
syndrome itself. We tested for the interaction between UA and overweight using two-way 
cross products between the continuous UA variable and an indicator variable of BMI < 25 
kg/m2 vs. BMI ≥ 25 kg/m2 for each component of MetS and the syndrome as a whole. Cox 
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proportional hazard models were used in Paper 2 to assess the association between the UA 
levels and the clinical endpoints at different levels of DD. We tested for the interaction 
between UA and each echocardiographic marker of DD using two-way cross products 
between the continuous UA variable and indicator variables of each echocardiographic 
marker of DD. In Paper 3, logistic regression and fractional polynomial models were applied 
to examine the sex-specific differences in the association between the adiponectin levels and 
DD. We tested for interaction between sex and adiponectin for the association with DD 
indices using two-way cross products between sex and adiponectin as a continuous variable 
and as an indicator variable (low sex-specific tertile vs. two upper tertiles). A two-sided P-
value of < 0.05 was considered significant. We performed all analyses with SPSS software 
(IBM Corp., released 2013, IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: 
IBM Corp and IBM Corp., Released 2015, IBM SPSS Statistics for Windows, Version 23.0. 
Armonk, NY: IBM Corp), with the exception of the polynomial fractional analyses in Paper 3, 
which were conducted with Stata software (StataCorp., 2015, Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). 
4.5 Ethical considerations 
The Regional Committee for Medical Research Ethics approved the study, and all 
participants provided written consent for participation in each survey. 
5 Main results 
5.1 Paper 1: Overweight modifies the longitudinal association 
between the uric acid levels and some components of 
metabolic syndrome: The Tromsø Study 
The main finding of this paper was that elevated UA levels were associated with the 
development of elevated blood pressure in overweight subjects (BMI ≥ 25 kg/m2) over a span 
of seven years (odds ratio [OR] of 1.44 per 59 µmol/L UA increase at baseline, 95% 
confidence interval [CI] = 1.17-1.77, P = 0.001). In individuals with a normal weight (BMI < 25 
kg/m2), UA levels were not associated with the development of elevated blood pressure, and 
the P-value for the interaction between the UA level and the dichotomized BMI variable was 
0.04. This finding was the same for the development of elevated fasting glucose levels over 
seven years. In the overweight subjects, UA levels were associated with the development of 
this MetS component (OR of 1.20 per 59 μmol/L increase in the UA levels, 95% CI = 1.10–
1.32, P < 0.001), but not in individuals with a normal weight, and the P-value for the 
interaction between the UA level and the BMI cut-off was 0.01. These results are presented 
in Figure 4, along with the association between the UA levels and other components of MetS 




Figure 4. Multivariate binary logistic regression models and baseline uric acid levels as a predictor of MetS and its 
components after seven years, stratified into normal-weight and overweight groups by BMI. The OR is reported 
as a 59 µmol/L increase in the uric acid level. Whiskers represent the 95% confidence interval. The group 
includes subjects without each component of MetS of interest or MetS at baseline. Covariates: sex, age, systolic 
blood pressure, total cholesterol, current smoking, physical activity, HbA1c, eGFR, alcohol consumption, use of 
diuretics, and waist circumference at baseline. * P-value for the interaction with the BMI cut-off < 0.05. 
Abbreviations: eGFR, estimated glomerular flitration rate; HbA1c, haemoglobin A1c; HDL, high-density 
lipoprotein; BMI, body mass index; MetS, metabolic syndrome. 
Although a significant difference between the overweight and normal-weight groups was not 
observed, the figure clearly shows that the UA level was associated with the development of 
MetS after seven years. Among the group of subjects without MetS at baseline (n = 3,660), 
611 individuals developed MetS seven years later, and the UA levels predicted the outcome 
(OR of 1.29 per 59 μmol/L increase in the UA levels, 95% CI = 1.18–1.41, P < 0.001). We 
also examined whether a change in the UA level over seven years was a predictor for MetS 
and obtained supporting results (OR of 1.28 per 59 µmol/L increase in the UA levels between 
1994 and 2001, 95% CI = 1.16-1.42, P < 0.001). There were no interactions between UA and 
sex or UA and an indictor variable of obesity (BMI < 30 kg/m2 vs. BMI ≥ 30 kg/m2) for any of 
these analyses. 
5.2 Paper 2: Uric acid levels predict mortality and ischaemic 
stroke in subjects with diastolic dysfunction: The Tromsø 
Study 1994-2013 
After the 19-year follow-up period, UA levels predicted all-cause mortality in subjects with an 
E/A ratio < 0.75 (hazard ratio [HR] of 1.12 per 59 µmol/L increase in the UA levels at 
baseline, 95% CI = 1.00-1.25) or E/A ratio > 1.5 (HR of 1.51 per 59 µmol/L increase in the 
UA levels at baseline, 95% CI = 1.09-2.09, P-value for the interaction between the E/A ratio 
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Figure 5. Multivariate Cox proportional hazards model and hazard ratios for all-cause mortality in subjects with 
low, normal and high E/A ratios per 59 µmol/L increase in the uric acid levels. Whiskers represent the 95% 
confidence intervals. Covariates: Sex, age, body mass index, mean systolic blood pressure, mean diastolic blood 
pressure, total cholesterol, triglycerides, eGFR, HbA1c, smoking, physical activity, and use of antihypertensive 
medication. Abbreviations: e, events; eGFR, estimated glomerular flitration rate; HbA1c, haemoglobin A1c. 
UA levels also predicted all-cause mortality in individuals with an EDT < 140 ms or > 220 ms 
(HR of 1.46 per 59 µmol/L increase in the UA levels at baseline, 95% CI = 1.01-2.12 and HR 
= 1.13, 95% CI = 1.02-1.26; P-value for the interaction with the EDT category = 0.04). In 
participants with an isovolumetric relaxation time (IVRT) ≤ 60 ms, the all-cause mortality risk 
was higher as the UA levels increased (HR of 4.98 per 59 µmol/L increase in the UA levels at 
baseline, 95% CI = 2.02-12.26, P-value for the interaction with the IVRT category = 0.004). 
Finally, the UA levels predicted ischaemic stroke in subjects with severely enlarged LA (HR 
of 1.62 per 59 µmol/L increase in the UA levels at baseline, 95% CI = 1.03-2.53, P-value for 
the interaction with the LA size category = 0.047). An interaction between the UA levels and 
any marker of DD was not observed for myocardial infarction, and interactions between sex 
and echocardiographic markers of DD or UA level were not observed in these analyses. 
5.3 Paper 3: Low adiponectin levels are associated with 
diastolic dysfunction in women: The Tromsø Study 
Each 1 µg/mL decrease in the adiponectin levels was associated with DD index average 
tissue Doppler e’ < 9 and E/e’ ratio ≥ 8 in women (OR of 1.17 per 1 µg/mL decrease in the 
adiponectin levels, 95% CI = 1.04-1.30, P = 0.01 and OR of 1.12 per 1 µg/mL decrease in 
the adiponectin levels, 95% CI = 1.02-1.24, P = 0.02). These associations were not observed 
in men (OR of 0.99 per 1 µg/mL decrease in the adiponectin levels, 95% CI = 0.85-1.16, P = 
0.93 and OR of 0.90 per 1 µg/mL decrease in the adiponectin levels, 95% CI = 0.78-1.03, P 
= 0.13). These analyses are presented in Figure 6. The P-values for the interactions between 
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Figure 6. Multivariate binary logistic regression models segregated by sex, with an average e’ < 9 and E/e’ ratio ≥ 
8 as dependent variables. The odds ratios are presented per 1 µg/mL decrease in the adiponectin levels. 
Whiskers represent the 95% confidence intervals. *P-value for the interaction with sex < 0.05. Covariates: Age, 
sex, waist circumference, mean systolic blood pressure, mean diastolic blood pressure, blood pressure lowering 
drugs, total cholesterol, high-density lipoprotein, triglycerides, estimated glomerular filtration rate, physically 
active, daily smoker, albumin-creatinine ratio and uric acid. 
Adiponectin levels in the lower sex-specific tertile were also associated with DD in women 
and with an increased odds of concentric LV hypertrophy (OR = 2.44, 95% CI = 1.03-5.78, P 
= 0.04). In men, the odds were decreased for the same outcome (OR = 0.32, 95% CI = 0.11-
0.89, P = 0.03, P-value for the interaction with sex = 0.002). Moreover, the adiponectin levels 
in the lower tertile were associated with a lower odds of eccentric LV hypertrophy in men (OR 
= 0.53, 95% CI = 0.33-0.88, P = 0.02), but not women (OR = 1.07, 95% CI = 0.71-1.62, P = 
0.74, P-value for the interaction = 0.02). Additionally, the adiponectin levels in the lower 
tertile were associated with a moderately enlarged LA in women (OR = 1.43, 95% CI = 1.01-
2.03, P = 0.04) but not in men (OR = 1.01, 95% CI = 0.64-1.58, P = 0.98, P-value for the 
interaction with sex = 0.04). Finally, according to the multivariate fractional polynomial 
regression analysis, lower adiponectin levels were associated with an increased LV mass in 
women (fractional power -2, P = 0.001) but not men (P = 0.66, P-value for the interaction with 
sex = 0.01). There was no interaction between adiponectin and UA levels for the association 
with indices of DD. 
6 General discussion 
6.1 Methodological considerations 
6.1.1 Type I and Type II errors 
When examining statistical associations, researchers usually employ a null hypothesis, which 
is a hypothesis that states that the variables in question have absolutely no relationship99. 
The object of the statistical analyses is to accept or reject the null hypothesis. A Type I error 
is an incorrect rejection of the null hypothesis, i.e., to declare an association between 
variables that does not exist100. Conversely, a Type II error is to wrongly accept a false null 


















present100. In the studies performed in this thesis, we have regarded P < 0.05 as statistically 
significant, which is also known as an alpha level of 5%, indicating that the maximal 
probability of committing a Type I error is 5%, provided that bias or incorrect test 
assumptions are not present. A low alpha level is set to minimize Type I errors. However, 
there is a trade-off between the probabilities of a Type I error and a Type II error, and the 
lower the alpha level is set, the higher the probability of committing a Type II error100. The 
convention is to set an alpha level of 5%, which in itself is an arbitrary value100, but it seems 
to offer a compromise in the trade-off between the probability of Type I and Type II errors. 
The large study populations assessed in the papers in this study protect against Type II 
errors. However, our stratifications of the cohorts, which were performed in all three papers, 
increase the probability of Type II errors. 
6.1.2 Study validity 
The object of epidemiological research is to obtain a precise and valid estimation of the 
frequency of a disease or the effect of an exposure on the occurrence of a disease in the 
general population100. A further objective, which is also the objective of this thesis, is often to 
obtain an accurate estimate that is generalizable to relevant target populations. The notion of 
an accurate estimate implies an estimate with little error. Estimation errors may be classified 
as either random or systematic100. An estimate that has little random error may be described 
as precise100. Systematic errors in estimations are also known as biases100. An estimate with 
little systematic error may be described as valid100. The study validity is the degree to which 
the conclusions drawn from the study are reasonable when the study methods and study 
population are considered99. The two fundamental types of study validity are external validity 
and internal validity99. Internal validity is the validity of the conclusions drawn from the study 
as they apply to the source population from which the study population was derived100. 
External validity is the validity of the conclusions drawn from the study as they apply to 
subjects outside of the source population100. 
6.1.2.1 External validity 
This concept is synonymous with generalizability and is an important point to discuss in 
articles that stem from The Tromsø Study. The population of The Tromsø Study is mostly 
comprised of Caucasian, middle-aged to elderly and healthy individuals, and the external 
validity of the study may be reduced because of this lack of demographic diversity. 
6.1.3 Bias  
Bias is the lack of internal validity, and there are three main categories of bias: selection bias, 
information bias and confounding bias100,101. 
6.1.3.1 Selection bias 
Selection bias occurs when the study population is not representative of the target 
population102. Specifically, for The Tromsø Study, selection bias is present when the 
participants of the study have a different relationship between exposure and outcomes than 
the subjects who were eligible for the study, including individuals who did not participate. All 
individuals 25 years and older who were registered as living in the Tromsø municipality were 
invited to participate in Tromsø 492. After excluding individuals who died or moved away from 
Tromsø, 23% of the eligible population did not participate in the survey92. These individuals 
were younger than the eligible population (mean age of 44.1 years vs. 47.2 years for women 
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and 40.9 years vs. 46.6 years for men)92. The non-participants also included a higher 
proportion of males (54% vs. 47%)92. Other researchers have also found lower participation 
rates for the younger age groups than for older age groups in population-based studies103. 
Legal restrictions hindered analyses of morbidity and mortality among the non-participants in 
the Tromsø Study; however, the following indicates that the consistent participants may have 
been healthier: Age- and sex-adjusted mortality for subjects who participated in all three 
Tromsø surveys 2-4 was 6.9/1,000 person-years; however, it was 11.1/1,000 person-years 
for individuals who were invited to participate in all three surveys but only participated in 
Tromsø 492. Other researchers have also observed higher death rates in non-participants 
than in participants104,105. The study population in Paper 1 and the basis for the study 
population in Paper 2 were the subjects who attended the special study of Tromsø, in which 
all men aged 55–74 years and women aged 50–74 years, as well as smaller (5–8%) random 
samples of the other age groups aged < 85 years were invited to participate. Twenty-six 
percent of the eligible population did not participate in this special study. We may speculate 
that individuals who participated in both surveys of Tromsø 4 were even healthier than the 
individuals who only participated in the first survey. Thus, a risk of selection bias was present 
due to divergence of health, age and gender of the non-participating population and the 
participating population, as well as the age selection criteria used for the special study. The 
same concern applies to the subsequent Tromsø Studies. The study population in Paper 1 
consists of subjects who participated in the special study of Tromsø 4 and returned for 
follow-up seven years later in Tromsø 5; 15% of the eligible population did not participate. 
The non-participating population also here tended to be younger and male92. Paper 3 
examines the cross-sectional data from Tromsø 6, and with the exception of the recently 
completed Tromsø 7, this study was the Tromsø Study with the lowest participation rate of 
34% for invited subjects who did not participate. Subjects were invited according to age, and 
with the exception of the age groups of 40-42 and 60-87 years, samples were available from 
the other age groups. The study populations for Paper 3 comprised subjects that participated 
in the special study of Tromsø 6, for which the invitation was based on age groups; 36% of 
the eligible population did not participate. If these losses to follow-up differ in exposure and 
outcomes from the rest of the cohort, they may introduce selection bias. Because both 
younger people, who are more likely to be healthy than older people, and unhealthier 
subjects tend to decline participation, the total effect of the biases is difficult to predict.  
Some subjects have missing values, which will subsequently exclude them from the 
multivariate analyses. These missing data may constitute bias if the persons with complete 
data for the analyses do not represent the target population102. However, the distribution of 
missing values does not appear to differ for the groups compared in our models.  
6.1.3.2 Information bias 
Information bias occurs during data collection and denotes a flaw in measuring exposure, 
covariate or outcome variables that results in different information accuracy between the 
groups of the study population being compared99,102. For categorical variables, information 
bias is called misclassification. Much of our data were derived from self-administered 
questionnaires. Some of the covariates in our models are based on subjects reporting 
potentially embarrassing or socially undesirable behaviours, such as smoking habits, alcohol 
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consumption and physical activity, and may be subject to so-called underreporting bias102. 
Questions may have been misunderstood, thus leading to possible misclassification.  
Another possible scenario for misclassification occurs during the allocation of subjects to 
binary variables. In the papers, we attempted to minimize this bias by treating most 
covariates, except for the lifestyle categories and medication use, as continuous variables. 
However, some biological variables were treated as categorical variables. In Paper 1, for 
example, the diagnosis of MetS consists of five components, in which all biological variables 
were dichotomized. The practice of dichotomizing continuous variables for use in multiple 
regression analyses is controversial, and some researchers have argued that this practice 
should be avoided106. The main concern is a loss of statistical power106. However, the loss of 
statistical power is more of a concern in studies with smaller samples106 than in studies with 
larger samples such as the samples assessed in this thesis. Furthermore, the process of 
dichotomizing continuous variables is widely performed in clinical research and clinical 
practice, and is sometimes unavoidable, as in the case of MetS, for which diagnosis of the 
syndrome relies on the simplistic yes/no answers to five component factors. This observation 
is also true for markers of DD, for which the cut-off values are designated according to 
guidelines. With the exception of the low adiponectin levels described in Paper 3, the 
dichotomization of continuous variables was not data-driven but rather was performed 
according to clinical guidelines. 
In particular, the use of non-fasting blood samples raises the risk of misclassification 
regarding the elevated fasting glucose and triglyceride levels, as discussed further below. 
We used the mean of the second and third blood pressure measurements to reduce the risk 
of misclassification for the elevated blood pressure variable. Information bias may also occur 
as measurement error, as inaccuracy and biological variability may occur in laboratory 
values. This error may cause other dichotomized variables, such as the low HDL category in 
the diagnosis of MetS in Paper 1, the echocardiographic markers of DD in Papers 2 and 3, 
the low adiponectin levels in Paper 3 and Paper 3 and the albuminuria category in Paper 3, 
to be misclassified. However, there is no reason to believe that these measurement errors 
are related to exposure or are dissimilarly distributed between the comparison groups, and 
the concern about these errors as a source of bias are therefore reduced. 
6.1.3.3 Confounders 
Confounding (also called confounding bias) occurs when all or part of the apparent 
relationship between exposure and outcomes is accounted for by other variables (also 
known as confounders) that affect the outcome but that are not affected by the exposure99. 
This effect may overestimate the effect of the exposure on the outcomes, known as positive 
confounding, or underestimate it, known as negative confounding99. Researchers must adjust 
for possible confounders in the statistical models to reduce the confounding bias. In our 
models, we included several covariates that are possible confounders, based on known risk 
factors for MetS and cardiovascular disease. However, we cannot completely exclude 
unmeasured confounders, particularly when we examine associations that have not been 




In this thesis, we have shown several associations between factors. However, the discovery 
of an association in epidemiological research is not sufficient to claim knowledge about 
cause and effect. Universal and objective criteria for causality have yet to be defined100, but 
the most rigorous method for testing a hypothesis available in epidemiology and medicine is 
the randomized controlled trial (RCT)99, which is the most appropriate method for assessing 
cause and effect. The cross-sectional design of Paper 3 has severe limitations regarding the 
assessment of causality. In this study design, we explored sex-specific associations between 
adiponectin levels and DD, but we could not generate inferences about causality. However, 
the prospective cohort study designs of Paper 1 and Paper 2 offer more information on 
possible cause and effect by allowing us to evaluate the temporal sequence. Namely, we 
established that elevated UA levels occurred before the outcome variable of interest, and 
temporality is a vital aspect when assessing causality99. 
6.1.5 The use of non-fasting blood sample values 
Participants in the Tromsø Studies were not given any special instructions regarding fasting 
before blood sampling. Thus, some subjects had fasted for at least eight hours since their 
last meal, but most had not, and all participants provided the time since their last meals. For 
example, the population in Paper 1 had a baseline median time since their last meal of 
between two and three hours, and eight hours had elapsed since the last meal for only 6.1% 
of the cohort. The lack of fasting blood samples is a particular concern for Paper 1, which 
relies on the correct diagnosis of MetS. Overall, our ability to establish the presence of 
elevated fasting glucose and triglyceride levels is affected by this limitation. Overnight 
fasting, as utilized in a study of MetS from 2013, is by far the best approach107. However, 
logistical considerations prevented us from obtaining fasting blood samples from most of the 
participants in the Tromsø Studies in 1994-95, 2001-02 and 2007-08. We adjusted the 
elevated fasting glucose and elevated triglyceride components of the MetS diagnosis to 
compensate for this limitation, as shown in Table 1. We have maintained the cut-off of ≥ 5.6 
mmol/L for elevated fasting glucose levels in the subjects for which at least four hours had 
elapsed since the last meal. We established a cut-off of ≥ 7.8 mmol/L for subjects for which 
less than four hours had elapsed since the last meal, which is the cut-off used for impaired 
glucose tolerance in oral glucose tolerance tests24. For the diagnosis of elevated 
triglycerides, we maintained a cut-off of ≥ 1.7 mmol/L if the time since the last meal was at 
least four hours, similar to the glucose levels. For subjects for which less than four hours had 
elapsed since the last meal, we set a cut-off for elevated triglyceride levels to ≥ 2.28 mmol/L, 
as non-fasting triglyceride levels are 20-30% higher than the fasting levels108. Using this 
method, we aimed to reduce the number of people misclassified in our study. 
6.1.6 Old data 
Both Papers 1 and 3 use the baseline data from Tromsø 4 in 1994-95, which may be a 
limitation of the articles. However, if our results can be reproduced in newer data, 
conceivably, our findings will be even more relevant to current trends, because risk factors 
such as overweight and obesity are even more prevalent now than in 1994-95. Moreover, the 
baseline data will be at least as old as the follow-up time in a long-term study. 
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6.1.7 The lack of tissue Doppler data for Tromsø 4 
Papers 2 and 3 both utilize echocardiographic data on DD from the Tromsø Study. However, 
the data were acquired 14 years apart, and some technological and echocardiographic 
progress was achieved during that time. Foremost is the addition of tissue Doppler 
diagnostics in Tromsø 6, and a lack of this technology in Tromsø 4. Tissue Doppler data, 
particularly the acquisition of e’-wave data and calculation of the E/e’ ratio, have become 
hallmarks of DD diagnostics9, and the lack of those parameters is a limitation of Paper 2 and 
somewhat restricts the comparison of the data presented in Papers 2 and 3. However, the 
battery of DD parameters used in Paper 2 is still adequate, as all markers are listed in the 
current guidelines of The American Society of Echocardiography as ideal parameters for the 
classification of DD38. 
6.1.8 Diameter-based left atrial size estimation 
The studies examining echocardiographic markers of DD, Papers 2 and 3, utilize an 
estimation of LA size based on M-mode measures. The best assessment is probably derived 
from 2D LA volumes, and the M-mode method may underestimate the LA size109. Although 
current guidelines state that estimations of LA size from M-mode measures may not always 
represent an accurate picture of the LA size, they also deem the measurement reproducible, 
based on a wealth of published data98. When echocardiography was performed for Paper 2 
in 1994, a generally accepted method for assessing LA size was not available. Although the 
lack of LA volume is a limitation for Paper 2, its absence from the baseline data is not 
surprising. In Paper 3, the data were acquired in 2007-08 and the limitation is more serious. 
However, the same measurement for LA size was used in the two studies, enhancing the 
comparability between the papers.  
6.2 Discussion of the results 
6.2.1 The modulatory effect of overweight on the relationship between 
the uric acid levels and metabolic syndrome 
The main finding of this paper was that the UA levels predicted the development of elevated 
blood pressure, according to the MetS criteria, in the overweight subjects but not in normal-
weight individuals. This phenomenon has not been examined in many other studies. A small 
study (n = 69) from the United Arab Emirates examined the univariable relationship between 
UA levels and the components of MetS in healthy, young females who were stratified into 
normal-weight (BMI ≤ 25 kg/m2), overweight (BMI > 25, < 30 kg/m2), and obese (BMI ≥ 30 
kg/m2) categories110. This study identified statistically significant correlations between UA 
levels and the waist circumference and triglyceride components only, and the associations 
were confined to the obese group. The authors did not identify significant correlations 
between the UA level and elevated blood pressure or elevated fasting glucose levels in the 
strata. However, this study differed from Paper 1 in several features; the previous study was 
much smaller, only featured healthy, young females, and did not examine a multivariate 
relationship between the UA levels and MetS components. A recent study assessed the 
ability of UA levels to predict future hypertension among more than 26,000 normotensive 
Japanese males aged 18-60 years, with a mean follow-up time of 7.2 years111, and did not 
find an interaction between the UA levels and BMI (< 25 kg/m2 vs. ≥ 25 kg/m2). This study 
was also different from ours in several aspects, which may explain the discrepancy between 
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the results and those in Paper 1. First, the Japanese study examined the relationship 
between UA levels and hypertension, which is defined as blood pressure ≥ 140/90 mm Hg, 
and not the MetS criterion for elevated blood pressure, which is defined as ≥ 130/85 mm Hg. 
Second, only males were included, the elderly were excluded, and, similar to the study from 
the United Arab Emirates, the ethnic profile was different. In the cohort assessed in Paper 1, 
an interaction between UA levels and a BMI-cut off for obesity (< 30 kg/m2 vs. ≥ 30 kg/m2) 
was not observed, which may be due to the small group of obese subjects in the cohort. As 
many as 57.9% of the subjects were overweight, but only 13.5% were obese, naturally 
reducing the power of the statistical analyses in the stratum of obese individuals. 
As mentioned in the Introduction, the association between UA levels and the development of 
hypertension has been repeatedly reported in previous studies, but the concept that this 
association is only present in overweight persons has not been thoroughly investigated. 
There are two main theories regarding how UA is associated with the development of 
hypertension, both of which involve oxidative stress112. First, the degradation of hypoxanthine 
to xanthine and xanthine to UA, which is catalysed by XO, may produce ROS. Therefore, 
increased ROS production by XO may be detected as increased serum UA levels. Second, 
UA itself has been shown to stimulate NADPH oxidase (NOX) activity and ROS production in 
cultured mouse adipocytes, followed by reduced nitric oxide (NO) bioavailability, this was 
triggered by intracellular uptake of extracellular UA113. ROS has been proposed to cause 
hypertension114. Rats with induced mild hyperuricaemia developed intrarenal oxidative stress 
and hypertension, and ROS scavengers attenuated the elevated blood pressure115. 
Increased oxidative stress is particularly detrimental when the antioxidant capacity is reduced 
by accumulated fat116, which may corroborate the findings presented in Paper 1. 
There are a few clinical studies in humans to support a causative role for UA or XO activity in 
hypertension. A study of 125 children 6 to 18 years of age referred for evaluation of 
hypertension found that 89 % of the children with primary hypertension had UA levels > 327 
µmol/L, but none of the children with white-coat hypertension or the controls had UA levels 
that high117. A randomized trial that enrolled 30 adolescents 11 to 17 years of age with newly 
diagnosed primary hypertension and UA ≥ 357 µmol/L, treated the subjects with allopurinol 
200 mg twice daily for four weeks, and placebo twice daily for four weeks, with a two-week 
washout period in between, or the other way around118. The study found that allopurinol 
significantly reduced systolic and diastolic blood pressure, compared to placebo, and 20 of 
the participants were rendered normotensive during allopurinol treatment vs. one participant 
while taking placebo. The same investigators conducted a double-blinded RCT that enrolled 
60 prehypertensive (blood pressure ≥ 120/80 mm Hg and < 140/90 mm Hg), obese (> 95th 
percentile for sex and age) adolescents 11 to 17 years of age with UA ≥ 297 µmol/L, and 
treated them with either allopurinol 200 mg twice daily, the uricosuric drug probenecid 500 
mg twice daily or placebo twice daily for seven weeks119. The study found that both 
allopurinol and probenecid significantly and markedly reduced blood pressure compared to 
placebo (mean reduction in systolic blood pressure 10.2 mm Hg and mean reduction in 
diastolic blood pressure 9.0 mm Hg). There was no significant difference in blood pressure 
reduction between allopurinol and probenecid, and this points to a non-XO mediated 
mechanism, and implicates UA as the biochemical mediator of increased blood pressure in 
this study. A study that enrolled 59 hyperuricaemic adults with UA > 416 µmol/L that received 
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allopurinol 300 mg per day for three months found that allopurinol slightly but significantly 
reduced systolic and diastolic blood pressure120. That the effect of UA-lowering therapy on 
blood pressure seems to be greater in younger people, has led some investigators to 
theorize that early hyperuricaemic hypertension is UA dependent, but later becomes salt-
sensitive as renal microvascular disease and interstitial inflammation develops, and this 
hypertension is less sensitive to UA-lowering therapy112. 
As shown in this study, hyperuricaemia occurred before the onset of elevated blood pressure 
and elevated fasting glucose levels in overweight subjects, but the prospective 
epidemiological design of the study restricts our ability to make inferences about causality. 
We do not know whether the onset of these MetS components occurs because of elevated 
UA levels or whether UA is a bystander in the process. However, UA is associated with the 
development of metabolic derangements, which poses a greatly enhanced risk of 
cardiovascular disease, particularly in overweight subjects. This finding requires further 
analysis. 
6.2.2 Uric acid levels as a predictor of adverse cardiovascular events 
After a 19-year follow-up period, Paper 2 showed that elevated serum UA levels were 
associated with increased mortality and the incidence of ischaemic stroke in persons with 
echocardiographic indices of DD. As the baseline UA levels increased, subjects with an 
increased or a decreased E/A ratio, increased or decreased EDT, or reduced IVRT all had a 
higher risk of death during the follow-up period. In persons with severely enlarged LA, the 
risk of ischaemic stroke increased with higher baseline UA levels. ROS are also implicated in 
the association between UA levels and DD. NO bioavailability may be limited by ROS, and 
this phenomenon has been proposed to eventually lead to cardiac remodelling and DD, as 
well as endothelial dysfunction121. Experimental studies have implicated XO-derived ROS in 
the pathology of HF, both by showing increased XO activity in the failing heart and by 
showing that XO inhibition improves survival in animal models of HF122. An RCT conducted in 
405 subjects examined whether the XO inhibitor oxypurinol improved mortality, morbidity and 
quality of life in patients with HFrEF to a greater degree than the placebo after 24 weeks123. 
XO inhibition did not benefit unselected patients, but a subgroup with UA levels ≥ 565 µmol/L 
who were treated with oxypurinol experienced clinical improvement compared with the status 
of patients given the placebo. Building on this finding, another RCT of 253 patients with 
HFrEF and UA levels ≥ 565 µmol/L studied whether the XO inhibitor allopurinol improved 
survival or HF symptoms and signs after 24 weeks124. The study did not find a clinical benefit 
of allopurinol. Although XO inhibition was associated with improved survival in a large 
epidemiological study of patients with both HFpEF and HFrEF125, no larger randomized trial 
has yet demonstrated the efficacy of XO inhibition, or UA-lowering drugs in general, on the 
clinical outcomes of patients with HF. However, UA itself, and not XO, may be the culprit in 
cardiovascular disease. In one study, the endothelial function of hyperuricaemic subjects 
(mean UA 553 µmol/L) was reduced relative to that of the controls, possibly due to reduced 
vascular NO activity, which was alleviated with allopurinol treatment126. The study 
hypothesized that reduced UA levels and not inhibition of ROS production by XO, mediated 




Hypertension is a well-established risk factor for cardiovascular disease127, and some 
researchers hypothesize that the possible link between UA levels and cardiovascular disease 
is mediated by the risk posed by hypertension61. This hypothesis could be true for the 
specific association between UA levels and DD because hypertension is closely associated 
with DD11, and both hypertension and DD are implicated in the development of HFpEF39. 
However, the models in this study adjusted for both systolic and diastolic blood pressure, as 
well as the use of blood pressure-lowering drug, so any link between UA levels and DD 
mediated by hypertension is through other mechanisms not measured at baseline. 
Hyperuricaemia has been shown to downregulate the production of adiponectin18, an anti-
inflammatory and insulin-sensitizing agent produced by adipocytes, as described above. Low 
levels of adiponectin are associated with the development of hypertension80 and insulin 
resistance79 and may partially explain why UA levels are associated with the new onset of 
elevated blood pressure in Paper 1 and adverse outcomes in subjects with DD in Paper 2. 
Unfortunately, the serum adiponectin levels were not measured in the fourth wave of the 
Tromsø Study, and we were therefore unable to corroborate this theory. 
This study showed a relationship between UA levels and the risk of mortality in subjects with 
echocardiographic markers of DD, but not in subjects without these markers. We do not 
know whether hyperuricaemia is the cause of the enhanced mortality risk in persons with 
indices of DD. However, UA levels are associated with worse outcomes in subjects with DD, 
which is closely associated with metabolic disorders such as obesity, diabetes mellitus and 
MetS, further supporting the hypothesis that UA levels are associated with cardiovascular 
disease, particularly in subjects with conditions associated with metabolic derangements.  
Previous work by our research group did not identify UA as a risk factor for myocardial 
infarction66, and this finding did not change when we tested for interactions between UA 
levels and indices of DD for myocardial infarction in Paper 2. Both studies rely on a thorough 
review of the above-described endpoints. Therefore, when there is adequate control for 
confounders and a solid endpoint registry, our research offers no reason to consider UA as a 
risk factor for myocardial infarction, in contrast to other publications65,128. This indicates that 
the higher all-cause mortality with increasing UA in subjects with DD discovered in Paper 2, 
is through other processes than myocardial infarctions. 
6.2.3 Low adiponectin levels as a sex-specific predictor of DD 
This article reported the novel concept that the association of low adiponectin levels and DD, 
including several echocardiographic markers of DD and LV mass, was generally confined to 
the female sex. In men, the opposite trend was observed; all markers of DD were associated 
with higher adiponectin levels in men. Traditionally, high adiponectin levels have been 
regarded as favourable in terms of cardiac health, but research has challenged this 
perspective, and the role and action of adiponectin in heart disease is not clear. In general, 
low levels of adiponectin have been associated with the development of coronary heart 
disease in healthy subjects129, but high adiponectin levels are a risk factor for the severity of 
HF and mortality in patients with chronic HF82. One study following 3,263 relatively young 
persons for a mean time of 10.4 years found that higher adiponectin levels were associated 
with an increased risk of cardiovascular death and all-cause mortality (with no significant sex 
differences), although higher adiponectin levels were associated with a lower LV mass and a 
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lower prevalence of MetS130. Our findings demonstrating a relationship between adiponectin 
levels and some indices of DD in the cohort as a whole are supported by several 
epidemiological studies. One study examining 275 subjects with essential hypertension and 
normotensive controls found a negative association between adiponectin levels and LV mass 
and DD (defined as an E/A ratio > 1, IVRT > 100 ms and EDT > 200 ms)131. However, 
another study examining the adiponectin levels in 26 patients (20 of them male) with 
hypertrophic cardiomyopathy found that adiponectin was positively correlated with DD (with 
LV pressure half-time as a marker of myocardial relaxation)132. In a cross-sectional study 
involving participants of the Framingham Offspring study (n = 2,615), adiponectin levels were 
inversely correlated to LV mass but not LA enlargement90. In another cross-sectional, 
population-based study (n = 843), adiponectin did not mediate the association between 
visceral fat and DD133. A recent study (n = 100) reported low levels of adiponectin in patients 
with DD, and even lower levels in patients with DD and diabetes as a sign of early diabetic 
cardiomyopathy (DD was defined by the E/A ratio)134. One theory for this equivocal 
relationship between adiponectin and heart disease is that high levels are beneficial in 
healthy subjects, but adiponectin levels are upregulated as a compensatory mechanism 
during chronic HF83 or increase simply due to reduced kidney function, which commonly 
coexists with heart failure135. However, one fairly recent small study examining 25 patients 
with mild or moderate symptoms of HF compared with 25 healthy controls found a significant 
and negative relationship between DD and adiponectin levels (DD was defined as an E/A 
ratio < 1 and EF > 50%)136. Moreover, as a further complication, one study observed a 
concomitant increase in the plasma brain natriuretic peptide (BNP) and adiponectin levels in 
healthy subjects, and the authors argue that adiponectin levels are also a positive indicator of 
reduced cardiac function in healthy persons137. The relationship between adiponectin levels, 
obesity, sex, and organ damage is a complex one, and further studies are clearly needed. 
Our results for the sex-specific association between the adiponectin levels and DD may shed 
some light on the biphasic relationship between the adiponectin levels and DD observed in 
studies with very unequal proportions of men and women and in studies that did not have 
sufficient power to examine the sex-specific differences. Few articles have studied the sex-
specific differences in the relationship between adiponectin levels and DD. One paper 
examined a cohort consisting of 193 patients undergoing cardiac catheterization for coronary 
artery disease and specifically assessed sex-specific differences. A negative relationship 
between adiponectin levels and DD was observed, but a significant sex-specific difference in 
this association was not observed138. A population-based study of 556 individuals did not find 
any association between DD and adiponectin levels for either sex139. 
We did not identify any significant interaction between adiponectin and UA levels for either 
sex or in the cohort as a whole. Thus, we were unable to corroborate the hypothesis that the 
interaction between UA levels and markers of DD for the endpoints in Paper 2 was in any 
way mediated by adiponectin levels. However, only the total adiponectin levels were 
available in Tromsø 6. Quantification of the HMW fraction of adiponectin may have yielded 
more information than the total adiponectin levels alone, and we cannot exclude an 
association between the levels of UA and the HMW adiponectin fraction. Another point worth 
discussing is that adiponectin levels also increase simply due to reduced kidney function, 
which commonly coexists with HF, and as mentioned above, this could explain the possible 
link between the UA and adiponectin levels. However, the eGFR was mostly normal in our 
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study, and we controlled for the eGFR in all our models. Thus, as a confounder, reduced 
kidney function was probably less of a concern in our results. Moreover, an obvious limitation 
of Paper 3 was the cross-sectional design. The associations discovered in this study should 
be re-examined in a study with a prospective design to assess whether the low adiponectin 
levels occur before DD in women. In summary, we discovered a sex-specific association 
between low adiponectin levels and indices of DD and increased LV mass, perhaps 
representing a small step towards deciphering why HFpEF tend to occur disproportionately in 
women, in addition to obese, diabetic and hypertensive subjects.  
7 Conclusions and perspectives 
We have shown that UA levels predicted the development of MetS during a seven-year 
period, consistent with previous studies. The novel findings of our study are that the UA 
levels predicted the development of elevated blood pressure and elevated fasting glucose 
levels in overweight subjects but not in people with a normal weight. UA levels were 
associated with a higher risk of mortality and ischaemic stroke in subjects with indices of DD 
than that found in individuals without these markers. Low adiponectin levels were associated 
with DD in women but not in men. There was no interaction between adiponectin and UA 
levels in the association with markers of DD.  
This thesis contributes to research linking UA levels with metabolic derangements and 
poorer prognosis in patients with cardiovascular disease. Although our prospective study of 
UA and MetS offers more information than a cross-sectional study – we now know that 
hyperuricaemia occurs before the onset of elevated blood pressure and elevated fasting 
glucose levels in overweight subjects – our findings cannot provide any information regarding 
the causality of the association. UA may be a causative factor for the development of MetS 
components and increased mortality and ischaemic stroke risk in subjects with DD, or it may 
be a marker of some other causative factor or factors. Based on previous publications, we 
proposed that one of these factors might be adiponectin, a hormone that was not measured 
in the Tromsø Study in 1994-95 and therefore was not included in Papers 1 and 2. However, 
we could not corroborate this theory when we examined the data from the Tromsø Study of 
2007-08 for Paper 3, and further prospective studies are needed. The sex-specific difference 
in the association between adiponectin levels and DD discovered in Paper 3 requires further 
examination due to the lack of information about the biological basis of the female 
preponderance in HFpEF. 
Based on the above, this thesis offers the following theories: 
• Uric acid is associated with the deterioration of existing metabolic disturbances, as 
shown in the development of MetS features in overweight subjects and poor outcome 
in subjects with DD with increasing UA. 
• Increased mortality risk with increasing UA levels in subjects with DD is not due to 
increased risk of myocardial infarction. 
• Adipose tissue dysfunction may be part of the pathology of HFpEF in women, and 
some of the reason for the sex difference in HFpEF. 
• There is no significant interaction between adiponectin and UA levels for the 
association with DD in the general population. 
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Our findings should spur further research on the topics described below.  
• Studies assessing pressure overloaded animal models, with both male and female 
animals, to address the effects of UA and adiponectin levels on adipose tissue and 
the development of DD and HFpEF. 
• A large-scale RCT examining UA-lowering therapy in subgroups of overweight 
subjects and subjects with DD or HFpEF.  
• Further investigations, including prospective observational studies, of the 
preponderance of women with HFpEF should focus on adiponectin and other 
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